Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International AB Announces Results from Three Different Studies Using Divitum?Tka Will Be Presented At SABCS 2021

11/19/2021 | 10:05am EST

Biovica announced that results from three different studies using DiviTum?TKa, including a budget impact model, will be presented at the breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum?TKa budget impact model. All studies focused on the role of DiviTum?TKa in monitoring treatment in women with metastatic breast cancer. Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor. P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)DiviTum?TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum?TKa results ? the usage of DiviTum?TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer. P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET). Additional results of the healthcare DiviTum?TKa Budget Impact Model show the potential for DiviTum?TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum?TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum?TKa test. P3-03-05 The budget impact of the DiviTum?TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer. The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.


ę S&P Capital IQ 2021
All news about BIOVICA INTERNATIONAL AB (PUBL)
2021Biovica International
AQ
2021Q2 Interim report - Promising results published at ESMO
AQ
2021Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
CI
2021Biovica International AB Provides Earnings Guidance for the Full Year 2021
CI
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
2021Biovica International
AQ
2021Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
2021Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
2021Biovica International
AQ
More news
Financials
Sales 2022 39,0 M 4,24 M 4,24 M
Net income 2022 -28,0 M -3,04 M -3,04 M
Net cash 2022 110 M 12,0 M 12,0 M
P/E ratio 2022 -37,9x
Yield 2022 -
Capitalization 1 068 M 116 M 116 M
EV / Sales 2022 24,6x
EV / Sales 2023 5,13x
Nbr of Employees 24
Free-Float -
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 37,50 SEK
Average target price 103,00 SEK
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOVICA INTERNATIONAL AB (PUBL)-9.42%116
EXACT SCIENCES CORPORATION-4.88%12 757
GUARDANT HEALTH, INC.-29.91%7 126
BGI GENOMICS CO., LTD.1.37%5 755
SEEGENE, INC.-1.31%2 606
INVITAE CORPORATION-29.21%2 447